<産業資料/調査レポートの題名> 2022年6月15日

嚢胞性線維症(CF)治療薬の世界市場:薬物クラス別(膵酵素サプリメント、粘液溶解薬、気管支拡張薬、CFTRモジュレーター)、投与経路別(経口、吸入)


◆英文タイトル:Cystic Fibrosis (CF) Therapeutics Market by Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, and CFTR Modulators) and Route of Administration (Oral and Inhaled): Global Opportunity Analysis and Industry Forecast, 2019-2026

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools & Models

Chapter 2: Executive Summary

2.1. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Porter’S Five Forces Analysis
3.3. Top Player Positioning
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Rise In Incidence Of Cystic Fibrosis (Cf)
3.4.1.2. Advancements In Therapeutics For Treatment Of Cystic Fibrosis

3.4.2. Restraints

3.4.2.1. Low Awareness In Developing Nations

3.4.3. Opportunity

3.4.3.1. Surge In R&D Towards The Development Of Novel Therapeutics

Chapter 4: Cystic Fibrosis Therapeutics Market, By Drug Class

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Pancreatic Enzyme Supplements

4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Analysis, By Country

4.3. Mucolytics

4.3.1. Key Trends And Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Analysis, By Country

4.4. Bronchodilators

4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Analysis, By Country

4.5. Cftr Modulators

4.5.1. Key Trends And Opportunities
4.5.2. Market Size And Forecast
4.5.3. Market Analysis, By Country

Chapter 5: Cystic Fibrosis Therapeutics Market, By Route Of Administration

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Oral

5.2.1. Market Size And Forecast
5.2.2. Market Analysis, By Country

5.3. Inhale

5.3.1. Market Size And Forecast
5.3.2. Market Analysis, By Country

Chapter 6: Cystic Fibrosis Therapeutics Market, By Region

6.1. Overview

6.1.1. Market Size And Forecast

6.2. North America

6.2.1. Key Trends And Opportunities
6.2.2. North America Market Size And Forecast, By Country

6.2.2.1. U.S. Market Size And Forecast, By Drug Class
6.2.2.2. U.S. Market Size And Forecast, By Route Of Administration
6.2.2.3. Canada Market Size And Forecast, By Drug Class
6.2.2.4. Canada Market Size And Forecast, By Route Of Administration
6.2.2.5. Mexico Market Size And Forecast, By Drug Class
6.2.2.6. Mexico Market Size And Forecast, By Route Of Administration

6.2.3. North America Market Size And Forecast, By Drug Class
6.2.4. North America Market Size And Forecast, By Route Of Administration

6.3. Europe

6.3.1. Key Trends And Opportunities
6.3.2. Europe Market Size And Forecast, By Country

6.3.2.1. Germany Market Size And Forecast, By Drug Class
6.3.2.2. Germany Market Size And Forecast, By Route Of Administration
6.3.2.3. Uk Market Size And Forecast, By Drug Class
6.3.2.4. Uk Market Size And Forecast, By Route Of Administration
6.3.2.5. France Market Size And Forecast, By Drug Class
6.3.2.6. France Market Size And Forecast, By Route Of Administration
6.3.2.7. Rest Of Europe Market Size And Forecast, By Drug Class
6.3.2.8. Rest Of Europe Market Size And Forecast, By Route Of Administration

6.3.3. Europe Market Size And Forecast, By Drug Class

6.4. Asia-Pacific

6.4.1. Key Trends And Opportunities
6.4.2. Asia-Pacific Market Size And Forecast, By Country

6.4.2.1. Japan Market Size And Forecast, By Drug Class
6.4.2.2. Japan Market Size And Forecast, By Route Of Administration
6.4.2.3. China Market Size And Forecast, By Drug Class
6.4.2.4. China Market Size And Forecast, By Route Of Administration
6.4.2.5. India Market Size And Forecast, By Drug Class
6.4.2.6. India Market Size And Forecast, By Route Of Administration
6.4.2.7. Australia Market Size And Forecast, By Drug Class
6.4.2.8. Australia Market Size And Forecast, By Route Of Administration
6.4.2.9. Rest Of Asia-Pacific Market Size And Forecast, By Drug Class
6.4.2.10. Rest Of Asia-Pacific Market Size And Forecast, By Route Of Administration

6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
6.4.4. Asia-Pacific Market Size And Forecast, By Route Of Administration

6.5. Lamea

6.5.1. Key Market Trends And Opportunities
6.5.2. Lamea Market Size And Forecast, By Country

6.5.2.1. Brazil Market Size And Forecast, By Drug Class
6.5.2.2. Brazil Market Size And Forecast, By Route Of Administration
6.5.2.3. South Africa Market Size And Forecast, By Drug Class
6.5.2.4. South Africa Market Size And Forecast, By Route Of Administration
6.5.2.5. Saudi Arabia Market Size And Forecast, By Drug Class
6.5.2.6. Saudi Arabia Market Size And Forecast, By Route Of Administration
6.5.2.7. Rest Of Lamea Market Size And Forecast, By Drug Class
6.5.2.8. Rest Of Lamea Market Size And Forecast, By Route Of Administration

6.5.3. Lamea Market Size And Forecast, By Drug Class
6.5.4. Lamea Market Size And Forecast, By Route Of Administration

Chapter 7: Company Profiles

7.1. F. Hoffmann-La Roche Ag

7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance

7.2. Novartis Ag

7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance

7.3. Gilead Sciences, Inc.

7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance

7.4. Vertex Pharmaceuticals Incorporated

7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.4.6. Key Strategic Moves And Developments

7.5. Abbvie Inc.

7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.5.6. Key Strategic Moves And Developments

7.6. Glaxosmithkline Plc.

7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance

7.7. Teva Pharmaceutical Industries Ltd.

7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance

7.8. Allergan Plc

7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance

7.9. Pharmaxis Ltd

7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio

7.10. Mylan N.V

7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark